Cilnidipine versus Amlodipine Randomized Trial for Evaluation in Renal Desease

UMIN ID: UMIN000000496

Registered date:04/10/2006

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: hypertensive patients with renal disease
• Date of first enrollment: 2002/07/01
• Target sample size: 400
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

cilnidine 10-20mg/day in combination with angiotensin receptor blocker (ARB) or angiotensin converting enzyme (ACE)inhibitor
amlodipine 5-10 mg/day in combination with ARB or ACEinhibitor

Outcome(s)

• Primary Outcome: Urinary protein as protein/creatinine ratio
• Secondary Outcome: Cardiovascular death Cardiovascular event

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1. Hypertensive emergency 2. Severe heart failure, severe arrhythmia, angina, myocardial infarction within 6 months of onset 3. Stroke within 6 months of onset 4. Severe diabetes mellitus 5. Prengnancy and possible pregnancy 6. History of severe side effect of calcium channel blocker, ARB, or ACE inhibitor 7. Patients who are treateing with cilnidipine or amlodipine 8. Patinets who are inadequate to entry this study by physicians in charge

Related Information

• Primary Sponsor: University of Tokyo Graduate School of Medicine
• Source(s) of Monetary Support: Department account fund